Showing 7,521 - 7,540 results of 18,479 for search 'significant ((((((gap decrease) OR (greater decrease))) OR (a decrease))) OR (mean decrease))', query time: 0.59s Refine Results
  1. 7521

    The flow chart of the study. by Lanxiang Pu (5924435)

    Published 2025
    “…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …”
  2. 7522

    Baseline characteristics of participants. by Lanxiang Pu (5924435)

    Published 2025
    “…Hematocrit in the first 2 hours of life, considered as a continuous variable, was significantly associated with short-term outcomes in univariate analyses (P < 0.05). …”
  3. 7523

    Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i> by Saroj Saroj (13749336)

    Published 2024
    “…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …”
  4. 7524

    Plant Extracellular Nanovesicle-Loaded Hydrogel for Topical Antibacterial Wound Healing <i>In Vivo</i> by Saroj Saroj (13749336)

    Published 2024
    “…In this regard, bioderived nanovesicles have shown significant promise. This work demonstrated significant antibacterial properties of extracellular nanovesicles derived from plant (mint) leaf juice (MENV). …”
  5. 7525
  6. 7526

    pHI for net status. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  7. 7527

    Combined net integrity PBO and LLINs-PLOS1. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  8. 7528

    Factors affecting pyrethroid-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  9. 7529

    Factors associated with mosquito net integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  10. 7530

    LLINs knockdown performance over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  11. 7531

    Factors affecting PBO-LLINs integrity. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  12. 7532

    Net bioefficacy data. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  13. 7533

    House structure and status. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  14. 7534

    LLINs hole positions over time. by Job Oyweri (22041452)

    Published 2025
    “…Against a Bungoma pyrethroid-resistant <i><i>Anopheles gambiae</i></i> s.s<i>,</i> mosquito mortality with pyrethroid-LLINs declined from 36.9% when new to 6.8% at 18 months, while PBO-LLINs dropped from 55.6% to 11.8%.…”
  15. 7535
  16. 7536

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  17. 7537

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  18. 7538

    Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

    Published 2025
    “…In ovariectomized mice, <b>5cc</b> administration (5 mg/kg) improved the trabecular microarchitecture, bone mineral density, and strength, at levels comparable to teriparatide, while significantly reducing bone resorption markers. With 13.57% oral bioavailability and selectivity for PDE1A1 (32% inhibition at 500 nM), <b>5cc</b> offers an innovative therapeutic candidate for PMO with a dual anabolic-antiresorptive profile and oral efficacy, warranting further clinical development.…”
  19. 7539

    Table 3_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”
  20. 7540

    Table 1_Ageing, clinical complexity, and exercise therapy: a multidimensional approach.docx by Salvatore Corrao (441339)

    Published 2025
    “…Ageing represents the primary risk factor for chronic degenerative diseases, especially involving cardiovascular, metabolic, respiratory, and osteoarticular systems, determining the decrease in activities and quality of daily life. Regular physical activity can significantly reduce the risk of chronic degenerative diseases, moderate or severe functional limitations, and premature death in older adults. …”